References
- Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006;24:983-91
- Ohtsu H, Suzuki H, Nakashima H, et al. Angiotensin II signal transduction through small GTP-binding proteins: mechanism and significance in vascular smooth muscle cells. Hypertension 2006; 48:534-40 https://doi.org/10.1161/01.HYP.0000237975.90870.eb
- Kim KB. The role of angiotensin receptor antagonist in patients with hypertension and cardiovascular diseases. Korean Circ J 1999;29:335-40 https://doi.org/10.4070/kcj.1999.29.3.335
- Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens Suppl 2005;23:S9-17 https://doi.org/10.1097/01.hjh.0000165623.72310.dd
- Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24:11-25 https://doi.org/10.1097/01.hjh.0000191244.91314.9d
- Weber MA. Hypertension treatment and implications of recent cardiovascular outcome trials. J Hypertens Suppl 2006;24:S37-44 https://doi.org/10.1097/01.hjh.0000220102.35025.eb
- Sokol SI, Portnay EL, Curtis JP, et al. Modulation of the reninangiotensin- aldosterone system for the secondary prevention of stroke. Neurology 2004;63:208-13 https://doi.org/10.1212/01.WNL.0000130360.21618.D0
- Sleight P, Yusuf S. New evidence on the importance of the reninangiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003;21:1599-608 https://doi.org/10.1097/00004872-200309000-00001
- Jeon ES. Role of angiotensin II receptor blockers in the treatment of congestive heart failure. Korean Circ J 2002;32:1039-45 https://doi.org/10.4070/kcj.2002.32.12.1039
- Mancia G. Total cardiovascular risk: a new treatment concept. J Hypertens Suppl 2006;24:S17-24 https://doi.org/10.1097/01.hjh.0000220099.12154.c1
- Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 2006;98:463-71 https://doi.org/10.1161/01.RES.0000205761.22353.5f
- Farmer JA. Renin angiotensin system and ASCVD. Curr Opin Cardiol 2000;15:141-50 https://doi.org/10.1097/00001573-200005000-00004
- Ulfendahl HR, Aurell M. Renin-Angiotensin: a centenary symposium of the discovery of the renin-angiotensin system. London: Portland Press; 1998. p.1-12
- Suh SY, Park CG, Chwe UR, et al. Plasma renin activity and clinical implication in Korean hypertensive patients. Korean Circ J 2005;35:658-64 https://doi.org/10.4070/kcj.2005.35.9.658
- Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE, Berk BC. Angiotensin II signal transduction and the mitogenactivated protein kinase pathway. Cardiovasc Res 1995;30:511-7 https://doi.org/10.1016/S0008-6363(95)00088-7
- Pan L, Gross KW. Transcriptional regulation of renin. Hypertension 2005;45:3-8 https://doi.org/10.1161/01.HYP.0000151886.26341.4b
- Rosendorff C. The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996;28:803-12 https://doi.org/10.1016/S0735-1097(96)00251-3
- Beierwaltes WH. Renin synthesis and secretion. In: Izzo JL, Black HR, editor. Hypertension Primer. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003. p.14-7
- Krum H, Gilbert RE. Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders. J Hypertens 2007;25:25-35 https://doi.org/10.1097/HJH.0b013e3280113950
- Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997;80: 607-16 https://doi.org/10.1161/01.RES.80.5.607
- de Leeuw PW. How do angiotensin II receptor antagonists affect blood pressure? Am J Cardiol 1999;84:5K-6K https://doi.org/10.1016/S0002-9149(99)00399-9
- Min LJ, Mogi M, Li JM, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005;97: 434-42 https://doi.org/10.1161/01.RES.0000180753.63183.95
-
Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived
$H_2O_2$ . Hypertension 2005;46:732-7 https://doi.org/10.1161/01.HYP.0000182660.74266.6d -
Ushio-Fukai M, Zuo L, Ikeda S, Tojo T, Patrushev NA, Alexander RW. cAbl tyrosine kinase mediates reactive oxygen species and caveolin-dependent
$AT_1$ receptor signaling in vascular smooth muscle. Circ Res 2005;97:829-36 https://doi.org/10.1161/01.RES.0000185322.46009.F5 - Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 2005; 112:2668-76 https://doi.org/10.1161/CIRCULATIONAHA.105.538934
- Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Phamacol 2002; 39:319-27 https://doi.org/10.1097/00005344-200203000-00001
- Calo LA, Pessina AC. RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone: evidence from studies in humans. J Hypertens 2007;25:259-64 https://doi.org/10.1097/HJH.0b013e328010d4d2
- Smith NJ, Luttrell LM. Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease. Hypertension 2006;48:173-9 https://doi.org/10.1161/01.HYP.0000232641.84521.92
- Yang CH, Lee SH, Park TH, et al. Gene expression profile of volume-overloaded human ventricular myocardium prior to developing heart failure. Korean Circ J 2005;35:649-57 https://doi.org/10.4070/kcj.2005.35.9.649
- Fleming I. Signaling by the angiotensin-converting enzyme. Circ Res 2006;98:887-96 https://doi.org/10.1161/01.RES.0000217340.40936.53
- Willenheimer R, Dahloef B, Rydberg E, Erhardt L. AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 1999;20:997-1008 https://doi.org/10.1053/euhj.1999.1547
- Hollenberg NK. Hypertension, small arteries, and pathways for angiotensin II generation. Circulation 2000;101:1641-2 https://doi.org/10.1161/01.CIR.101.14.1641
- Unger T, Culman J, Peter G. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens Suppl 1998;16:S3-9 https://doi.org/10.1097/00004872-199816010-00002
- Diez J. Profibrotic effects of angiotensin II in the heart. Hypertension 2004;43:1164-5 https://doi.org/10.1161/01.HYP.0000128620.57061.67
- Wolf G, Wenzel UO. Angiotensin II and cell cycle regulation. Hypertension 2004;43:693-8 https://doi.org/10.1161/01.HYP.0000120963.09029.ca
- Kim YH, Son JH, Piao H, et al. Role of angiotensin II type 1A receptor-mediated signaling in the development of pressure overload- induced left ventricular hypertrophy and fibrosis. Korean Circ J 2006;36:626-34 https://doi.org/10.4070/kcj.2006.36.9.626
- Kim KM, Kim IS, Park SJ, et al. Effects of angiotensin II on the growth of vascular smooth muscle cells. Korean Circ J 1999;29: 209-15 https://doi.org/10.4070/kcj.1999.29.2.209
- Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikreinkinin systems. Hypertension 2005;46:1236-42 https://doi.org/10.1161/01.HYP.0000193538.20705.23
- Sampaio WO, Souza dos Santos RA, Faria-Silva R, de Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49:185-92 https://doi.org/10.1161/01.HYP.0000251865.35728.2f
- Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-20 https://doi.org/10.1161/01.CIR.97.14.1411
- Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM, Witteman JC. ACE polymorphisms. Circ Res 2006;98:1123-33 https://doi.org/10.1161/01.RES.0000223145.74217.e7
- Goldberg LR, Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006;113:2851-60 https://doi.org/10.1161/CIRCULATIONAHA.105.600437
- Kahan T. The importance of left ventricular hypertrophy in human hypertension. J Hypertens Suppl 1998;16:S23-9 https://doi.org/10.1097/00004872-199816010-00005
- Alfakin K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006; 24:1223-30 https://doi.org/10.1097/01.hjh.0000234097.47379.fd
- Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005;23:S27-33 https://doi.org/10.1097/01.hjh.0000165625.79933.9a
- Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6 https://doi.org/10.1172/JCI114844
- Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DCPI) (dipeptidyl carboxypeptidase I). Nucleic Acids Res 1992;20:1433
- Rosendorff C. Vascular hypertrophy in hypertension: role of the renin-angiotensin system. Mt Sinai J Med 1998;65:108-17
- Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens 2001;10:617-24 https://doi.org/10.1097/00041552-200109000-00011
- Schulman IH, Zhou MS, Raij L. Cross-talk between angiotensin II receptor types 1 and 2: potential role in vascular remodeling in humans. Hypertension 2007;49:270-1 https://doi.org/10.1161/01.HYP.0000253966.21795.d3
- Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12 https://doi.org/10.1161/01.CIR.103.6.904